tozinameran bivalent

The BNT162b2 BA.4/5 bivalent vaccine is an mRNA-based COVID-19 vaccine developed by Pfizer and BioNTech as an updated formulation of their original tozinameran (BNT162b2) product[1][3][4]. This bivalent version contains two mRNA components—one encoding the spike protein of the original SARS-CoV-2 strain (wild-type), and one encoding the spike protein of the Omicron subvariants BA.4 and BA.5[5]. The mechanism of action involves delivery of these mRNAs into host cells via lipid nanoparticles; host cells then express the encoded spike proteins, eliciting a robust immune response including neutralizing antibodies against both wild-type and Omicron variants[3][6]. The primary indication is for prevention of symptomatic COVID-19 caused by SARS-CoV-2 in individuals aged 6 months or older as a primary series or booster dose[1][3]. Clinical data show that this formulation elicits higher neutralizing antibody titers against Omicron sublineages compared to monovalent vaccines and restores protection against a range of outcomes including those related to XBB-related sublineages[3][8].

Brand names

Comirnaty

Other names

Pfizer-BioNTech COVID-19 VaccinePfizer-BioNTech Comirnaty COVID-19 vaccineOmicron BA.4/BA.5-adapted bivalent COVID-19 vaccine